Ziv Tamar, Barnea Eilon, Segal Hava, Sharon Rivka, Beer Ilan, Admon Arie
Department of Biology, The Smoler Proteomics Center, Technion, Haifa, Israel.
Cancer Biomark. 2006;2(6):219-34. doi: 10.3233/cbm-2006-2601.
Small cell lung carcinoma (SCLC) is an aggressive, highly metastatic cancer with a strong tendency for chemotherapy resistance. Identification of proteins uniquely expressed in SCLC cells, can facilitate the development of new diagnostic tools, improve immunotherapy, and deepen our understanding of the underlying mechanisms of the disease. Here we describe a comparative proteomics analysis of ten SCLC cell lines and three controls lines, while searching for proteins preferentially expressed in SCLC cells as potential disease markers. Total protein extracts were compared by two-dimensional gel electrophoresis and by two-dimensional liquid chromatography resulting in the identification of 1093 proteins, 202 of which were detected only in the SCLC cells. These include proteins of different cellular functions, including cellular proliferation and known tumor antigens. Since SCLC has a neuroendocrine origin, of major interest are the identified proteins involved in nerve and brain embryonic development. These proteins are potentially valuable as both tumor markers and as antigens for immunotherapy.
小细胞肺癌（SCLC）是一种侵袭性强、具有高度转移性且对化疗耐药倾向明显的癌症。鉴定小细胞肺癌细胞中独特表达的蛋白质，有助于开发新的诊断工具、改善免疫治疗，并加深我们对该疾病潜在机制的理解。在此，我们描述了对十个小细胞肺癌细胞系和三个对照细胞系进行的比较蛋白质组学分析，同时寻找在小细胞肺癌细胞中优先表达的蛋白质作为潜在的疾病标志物。通过二维凝胶电泳和二维液相色谱对总蛋白提取物进行比较，共鉴定出1093种蛋白质，其中202种仅在小细胞肺癌细胞中检测到。这些蛋白质包括具有不同细胞功能的蛋白质，如细胞增殖相关蛋白和已知的肿瘤抗原。由于小细胞肺癌起源于神经内分泌，因此特别令人感兴趣的是那些参与神经和脑胚胎发育的已鉴定蛋白质。这些蛋白质作为肿瘤标志物和免疫治疗的抗原都具有潜在价值。
